Scholar Rock Holding (SRRK) Assets Average (2018 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Assets Average of $469.8 million for Q1 2026, up 6.46% year-over-year from $441.2 million in Q1 2025, and up 15.14% quarter-over-quarter from $408.0 million in Q4 2025.
Analysis
Scholar Rock Holding (SRRK) Assets Average (2018 - 2026) Analysis & Trends
Scholar Rock Holding's Assets Average history runs 9 years deep, the most recent figure standing at $469.8 million for Q1 2026.
- In Q1 2026, Assets Average rose 6.46% year-over-year to $469.8 million; the TTM figure through Mar 2026 stood at $469.8 million (up 6.46% YoY), while the FY2025 annual figure was $439.6 million, up 11.86% from the prior year.
- Assets Average for Q1 2026 stood at $469.8 million, up from $408.0 million in the prior quarter.
- The five-year high for Assets Average was $469.8 million in Q1 2026, with the low at $203.0 million in Q3 2024.
- The 5-year median for Assets Average is $336.4 million (2023), against an average of $337.2 million.
- The sharpest annual moves came in 2023 and 2025: Assets Average plunged 34.24% in 2023, then surged 85.16% in 2025.
- Scholar Rock Holding's Assets Average stood at $374.2 million in 2022, then slipped by 24.95% to $280.9 million in 2023, then grew by 16.44% to $327.0 million in 2024, then advanced by 24.76% to $408.0 million in 2025, then increased by 15.14% to $469.8 million in 2026.
- Business Quant data shows SRRK's Assets Average at $469.8 million in Q1 2026, $408.0 million in Q4 2025, and $375.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Scholar Rock Holding | 7.23 Bn | 7.23 Bn | - | 529.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 529.40 Mn |
| Mar 31, 2026 | 469.76 Mn |
| Dec 31, 2025 | 408.00 Mn |
| Sep 30, 2025 | 375.88 Mn |
| Jun 30, 2025 | 373.80 Mn |
| Mar 31, 2025 | 441.24 Mn |
| Dec 31, 2024 | 327.03 Mn |
| Sep 30, 2024 | 203.00 Mn |
| Jun 30, 2024 | 247.08 Mn |
| Mar 31, 2024 | 289.16 Mn |
| Dec 31, 2023 | 280.86 Mn |
| Sep 30, 2023 | 267.79 Mn |
| Jun 30, 2023 | 299.81 Mn |
| Mar 31, 2023 | 336.44 Mn |
| Dec 31, 2022 | 374.24 Mn |
| Sep 30, 2022 | 407.22 Mn |
| Jun 30, 2022 | 345.05 Mn |
| Mar 31, 2022 | 285.21 Mn |
| Dec 31, 2021 | 301.42 Mn |
| Sep 30, 2021 | 315.22 Mn |